Subscribe to Updates
Subscribe to our newsletter for the latest leadership tips, exclusive interviews, and expert advice from top CEOs. Simply enter your email below and stay ahead of the curve!.
Author: Daniel snow
U.S. dollar: Buy on the subpoena, sell on the indictment- StanChart Source link
USD/JPY: BofA sees yen weakness ahead of potential snap election Source link
China’s central bank likely to reverse FX measures as yuan strengthens Source link
EUR/PLN and USD/PLN price forecast for 2026, as per UBS Source link
Dollar edges higher ahead of CPI; yen drops sharply Source link
BofA sees AUD strength continuing as EUR/AUD downtrend has room to fall Source link
Asia FX slips as traders weigh Trump tariff threat, Iran unrest, Fed independence Source link
Dollar wobbles as markets fret about threat to Fed independence Source link
Japan finance minister says US Treasury’s Bessent shares concerns over weak yen Source link
In a Monday interview with CNBC’s Jim Cramer, Novo Nordisk CEO Mike Doustdar suggested the new pill format of the pharmaceutical giant’s weight loss drug will allow more people to use the medicine which had previously been available only as an injectable. “We are seeing, actually, that the pill is able to expand the market for a large group of people that have been waiting,” Doustdar said. “Predominantly, I would say the major barrier has been the taboo.”Many people have a needle phobia, Doustdar said, and he suggested that injectables have societal taboo. He also said injectable GLP-1s come with…